Healthcare Vendor Risk Management: HIPAA, FDA and ESG Obligations Explained 2026
What this guide covers: Healthcare vendor risk management is the process health systems, hospitals, pharmaceutical companies and health tech firms use to identify, assess and monitor risks from external vendors under five simultaneous regulatory frameworks: HIPAA and HITECH, FDA 21 CFR Part 820, ESG and Modern Slavery obligations, CMS Conditions of Participation, and the 2025 HIPAA Security Rule NPRM (90 FR 800) with its 240-day compliance window.
BAA requirements
2025 Security Rule update
FDA and medical devices
ESG obligations
Vendor types
The intelligence gap
Assessment process
Build a programme
How Neotas helps
FAQs
Last reviewed: May 2026 | Reading time: 22 minutes | Author: Neotas Intelligence Team
Average cost of a healthcare vendor-related breach (IBM/Ponemon, 2024)
Americans had data exposed in the 2024 Change Healthcare attack (Dallas Fed, 2025)
Vendors connected to the average hospital system (HIPAA Journal, 2026)
Compliance window for the 2025 HIPAA Security Rule NPRM once finalised (HHS, 90 FR 800)
What is healthcare vendor risk management?
Direct answer: Healthcare vendor risk management is the structured discipline of identifying, assessing and continuously monitoring the risks created by every external vendor, supplier and service provider across five concurrent regulatory obligations: HIPAA and HITECH (Protected Health Information), FDA 21 CFR (medical devices and pharmaceutical supply chains), ESG and Modern Slavery frameworks, CMS Conditions of Participation, and the 2025 HIPAA Security Rule NPRM (90 FR 800). It is not a cybersecurity function. It is a clinical, regulatory and operational discipline.
Most vendor risk programmes in healthcare were built to satisfy cybersecurity auditors. They run annual questionnaires, collect SOC 2 reports and file them in a shared drive. That approach was already inadequate before February 2024. After Change Healthcare, it is indefensible.
The core problem is a definitional one. Healthcare organisations treat vendor risk as a cybersecurity sub-function, so their programmes are designed to find cybersecurity gaps. They were never designed to find financial distress in a revenue cycle operator, beneficial ownership opacity in a medical device distributor, labour practice violations in a pharmaceutical API manufacturer, or the regulatory actions pending against a health IT vendor in a jurisdiction the questionnaire never asked about.
These are the risks that actually cause serious incidents. Standard TPRM frameworks, built for financial services, do not map onto healthcare’s regulatory overlay. The average hospital works with more than 1,000 vendors simultaneously, according to HIPAA Journal (2026). Each one represents a potential exposure point across all five regulatory domains at once. A programme that only addresses one of those domains is not a risk management programme. It is an incomplete checklist.
How healthcare vendor risk management differs from general TPRM
General third-party risk management focuses on cybersecurity, operational performance and commercial continuity. Healthcare vendor risk management carries the same obligations plus four additional layers that no other sector shares at this complexity:
- Patient safety as a direct stake. When an EHR vendor goes offline, patients cannot access care. When a medical device supplier is compromised, clinical equipment fails. Vendor failure in healthcare has clinical consequences, not just operational ones.
- Mandatory regulatory contracting. HIPAA requires a signed Business Associate Agreement (BAA) before any vendor touches Protected Health Information. That is not a best practice. It is a statutory requirement with penalties reaching $1.9 million per violation category per year under the HITECH enforcement structure. HHS OCR enforcement history shows covered entities fined specifically for inadequate vendor oversight, not just for breaches.
- FDA supplier qualification requirements. Medical device manufacturers must implement documented supplier qualification processes under FDA 21 CFR Part 820. Health systems procuring those devices must verify their suppliers’ FDA compliance status. This is an obligation that general vendor risk frameworks simply do not address.
- ESG and ethical supply chain obligations. UK organisations above the £36 million turnover threshold carry annual supply chain reporting duties under the Modern Slavery Act 2015. Pharmaceutical procurement teams face additional obligations under the EU’s Corporate Sustainability Due Diligence Directive (CSDDD). These are not aspirational commitments. They carry legal consequence.
For a full overview of the TPRM discipline and how healthcare fits within it, see the Neotas TPRM guide and the healthcare-specific TPRM platform overview.
Key takeaways
- Healthcare vendor risk management covers five simultaneous regulatory frameworks: HIPAA/HITECH, FDA 21 CFR, ESG/Modern Slavery, CMS Conditions of Participation, and the 2025 HIPAA Security Rule NPRM.
- Most healthcare programmes address only cybersecurity. The ESG, financial crime and financial stability layers are where the highest-impact incidents originate.
- Patient safety dependency distinguishes healthcare vendor risk from all other sectors: vendor failure here has direct clinical consequences.
- A BAA is legally required before any vendor handles PHI. Inadequate BAA oversight is itself a documented basis for HHS OCR enforcement action.
- The 2025 HIPAA Security Rule NPRM (90 FR 800) introduces a 240-day compliance window, mandatory MFA, encryption and tighter vendor oversight requirements once finalised.
Healthcare vendor risk management is a multi-regulatory discipline covering HIPAA, FDA, ESG and the emerging 2025 Security Rule requirements simultaneously. Programmes built only for cybersecurity compliance leave four of five regulatory obligations unaddressed, creating enforcement exposure across domains that questionnaire tools cannot see.
The regulatory obligation stack: five frameworks that apply simultaneously
Healthcare vendor risk management sits under five concurrent regulatory frameworks. HIPAA and HITECH govern PHI handling and impose mandatory BAA requirements. FDA 21 CFR governs medical device and pharmaceutical supplier qualification. ESG and Modern Slavery legislation impose supply chain due diligence duties. CMS Conditions of Participation set patient safety expectations. And the 2025 HIPAA Security Rule NPRM introduces new vendor oversight requirements with a 240-day compliance window once finalised.
The complexity of healthcare vendor compliance is not that any single framework is particularly difficult. It is that all five apply at once, each with its own assessment criteria, documentation requirements and penalty structure. A programme that satisfies HIPAA does not automatically satisfy FDA requirements for a medical device supplier. Both must be addressed, and they require different due diligence evidence.
HIPAA and HITECH: the core PHI protection framework
HIPAA’s Privacy Rule and Security Rule together require covered entities to verify that every vendor handling Protected Health Information implements appropriate administrative, physical and technical safeguards. The HITECH Act of 2009 extended these obligations directly to Business Associates and their sub-contractors, making fourth-party PHI exposure a statutory compliance requirement rather than just a risk management consideration.
The penalty structure is tiered by culpability. Violations through lack of knowledge carry fines of $100 to $50,000 per violation. Wilful neglect left uncorrected reaches the statutory maximum of $50,000 per violation with an annual cap of $1.9 million per violation category. Criminal penalties for intentional PHI misuse reach up to 10 years imprisonment. Critically, inadequate Business Associate due diligence is a standalone basis for HHS OCR enforcement action, independent of whether a breach occurred. See the full HHS OCR enforcement history for documented cases.
CMS Conditions of Participation
Medicare and Medicaid participating providers must meet CMS Conditions of Participation, which include information governance and patient safety requirements that directly influence vendor selection and oversight. A vendor whose failure creates a patient safety event can create CMS compliance consequences for the health system beyond the direct HIPAA penalties. Loss of Medicare and Medicaid certification is the ultimate enforcement outcome.
UK-specific obligations: Modern Slavery Act and CQC
UK healthcare organisations with annual turnover above £36 million carry reporting obligations under the Modern Slavery Act 2015, requiring annual supply chain transparency statements and active due diligence on supplier labour practices. The Care Quality Commission (CQC) imposes its own supplier oversight expectations for registered providers. UK pharma and medical device firms additionally face obligations under the Medicines and Healthcare products Regulatory Agency (MHRA) that parallel FDA requirements. See Modern Slavery Act 2015 at legislation.gov.uk.
| Framework | Applies to | Core vendor obligation | Penalty for failure |
|---|---|---|---|
| HIPAA Privacy Rule | All covered entities and BAs | BAA required before any PHI sharing; permitted uses defined | Up to $50,000 per violation; $1.9m annual cap per category |
| HIPAA Security Rule | All covered entities and BAs | Administrative, physical and technical safeguards verified at all ePHI-handling vendors | Same as Privacy Rule |
| HITECH Act | BAs and their sub-contractors | HIPAA obligations flow to sub-contractors; strengthened enforcement and direct liability | Up to $1.9m per violation category per year |
| FDA 21 CFR Part 820 | Medical device manufacturers | Supplier qualification, quality agreements, incoming inspection, periodic audits | Warning letters, consent decrees, product recalls, criminal prosecution |
| CMS Conditions of Participation | Medicare and Medicaid providers | Patient safety and information governance requirements influence vendor selection | Loss of Medicare and Medicaid certification |
| Modern Slavery Act 2015 | UK organisations with £36m+ turnover | Annual supply chain transparency statement; active due diligence on supplier labour practices | Court injunctions; reputational consequences; public registry non-compliance |
Five regulatory frameworks apply concurrently in healthcare vendor management. Satisfying one does not satisfy the others. The 2025 HIPAA Security Rule NPRM adds a sixth layer with binding requirements once finalised, covered in the next section.
The 2025 HIPAA Security Rule NPRM: what it changes for vendor management
On January 6, 2025, HHS published a Notice of Proposed Rulemaking (NPRM) at 90 FR 800, the most significant overhaul of the HIPAA Security Rule in over 20 years. Once finalised, covered entities and business associates have 240 days to comply. Key changes include mandatory MFA, encryption of ePHI at rest and in transit, 72-hour incident response and system restoration requirements, annual technology asset inventories, and tighter oversight of vendor security practices. The distinction between “required” and “addressable” safeguards is eliminated: all implementation specifications become mandatory.
This is the regulatory development that makes most existing healthcare vendor risk programmes immediately non-compliant once the rule finalises. HHS received over 4,000 public comments, with industry associations pushing back on implementation timelines. A final rule, potentially in modified form, is expected in 2026 with a 240-day compliance window from publication. HIPAA Journal tracking of the rulemaking progress provides the latest status.
Specific vendor management changes in the 2025 NPRM
The proposed rule directly affects how covered entities must manage business associates and their sub-contractors. The following requirements have explicit vendor oversight implications:
Critical change: Under the proposed rule, business associates must report security incidents to covered entities within 24 hours of discovery. Current BAA templates that allow “without unreasonable delay” notification are likely non-compliant once the rule finalises. Review and update BAA notification timelines now.
Mandatory MFA across all ePHI access points. The proposed rule requires multi-factor authentication on every system that stores, transmits or accesses ePHI, including EHR platforms, cloud services, medical devices and third-party vendor portals. Change Healthcare’s attackers exploited a legacy remote access portal without MFA enforcement. That specific vulnerability becomes a documented regulatory violation under the proposed rule. Covered entities must verify MFA enforcement at every Business Associate.
Encryption of ePHI at rest and in transit. The “addressable” designation that previously gave organisations flexibility on encryption is removed. Encryption becomes a required safeguard. This extends to every Business Associate’s systems handling ePHI: cloud providers, EHR vendors, billing services, and any sub-contractor in the PHI access chain.
Annual technology asset inventories. The proposed rule requires covered entities and business associates to maintain annually updated inventories of all technology assets with access to ePHI. For vendor risk programmes, this creates a new documentation requirement: the asset inventory must include third-party systems touching ePHI, effectively making vendor inventory a regulatory document rather than just a risk management tool.
72-hour incident response and system restoration. Tested business continuity plans that can restore critical systems within 72 hours of a disruptive event become mandatory. This directly addresses the Change Healthcare scenario, where healthcare organisations had no tested contingency for claims processing disruption lasting more than 72 hours.
Vendor security practice verification. The proposed rule requires annual compliance audits and tighter oversight of vendor security practices. Annual self-certification questionnaires are unlikely to satisfy this requirement once the rule is finalised. Independent verification of vendor security controls moves from best practice to regulatory expectation.
Counterintuitive observation
The 2025 NPRM eliminates the “addressable vs. required” distinction that many small and mid-size healthcare organisations relied on to defer encryption, MFA and other technical controls. Organisations that deliberately used “addressable” flexibility to avoid implementation costs face the greatest compliance gap. The rule does not grandfather existing practices.
The 2025 HIPAA Security Rule NPRM (90 FR 800) makes MFA, encryption, 72-hour incident response, annual asset inventories and tighter vendor oversight mandatory. The 240-day compliance window starts from publication of the final rule. Current annual-questionnaire-based vendor oversight programmes are structurally inadequate under the proposed requirements.
HIPAA Business Associate Agreement requirements: what a compliant BAA must contain
A HIPAA-compliant Business Associate Agreement (BAA) must contain eight mandatory provisions: permitted PHI uses and disclosures, prohibition on unauthorised use, minimum necessary standard, specified safeguards, breach notification timeline (within 60 days of discovery; many organisations contractually tighten this), sub-contractor obligations (required under HITECH), HHS audit cooperation rights, and PHI return or destruction procedures on termination. A missing provision creates a direct HIPAA compliance gap regardless of whether any incident occurred.
A BAA is not a substitute for vendor due diligence. It documents obligations. It does not verify that the vendor is meeting them. The distinction matters because HHS OCR has enforced against covered entities whose Business Associates failed, on the grounds that the covered entity’s oversight programme was inadequate, even where a valid BAA existed. The BAA is the floor of the legal relationship. Due diligence is the ceiling of the risk management relationship.
The eight mandatory BAA provisions
1. Permitted uses and disclosures of PHI. Defined specifically, not as an open-ended authorisation. The BAA must name the permitted purposes. Broad language such as “all services contemplated by the agreement” does not satisfy this requirement.
2. Prohibition on unauthorised use or disclosure. The Business Associate may not use or disclose PHI in any way not expressly permitted by the BAA or required by law.
3. Minimum necessary standard. The vendor accesses and uses only the PHI required for the specific contracted function. The BAA should specify how the vendor demonstrates compliance with this standard.
4. Appropriate safeguards. Administrative, physical and technical safeguards specified in the agreement. The proposed 2025 NPRM would require much greater specificity here: mandatory MFA, encryption requirements and vulnerability scanning cadence.
5. Breach notification timeline. Under current HIPAA rules, the Business Associate must notify the covered entity without unreasonable delay and no later than 60 days after discovery. Many organisations contractually require 24 or 48-hour notification. The 2025 NPRM proposes mandatory 24-hour notification. BAAs that use the 60-day default will require updating.
6. Sub-contractor obligations (HITECH extension). The BAA must require the Business Associate to impose equivalent safeguards on any sub-contractor that handles PHI on its behalf. This is where most covered entities have the largest gap: the BAA requires the obligation, but no one verifies it flows through to actual sub-contractors.
7. HHS audit cooperation. The Business Associate must make its internal practices, books and records available to HHS for compliance reviews. A vendor that refuses this provision cannot be used as a Business Associate.
8. PHI return or destruction on termination. At the end of the relationship, the vendor must return or securely destroy all PHI. The destruction must be documented. Verbal assurance does not satisfy this requirement.
The sub-contractor gap: where most BAAs fail
The Change Healthcare breach exposed this failure at scale. Most covered entities had compliant BAAs with Change Healthcare. The BAAs required Change Healthcare to impose equivalent safeguards on its own sub-contractors. Almost no covered entity had verified that this actually happened. The fourth-party dependencies, the cloud infrastructure, the sub-contracted processing partners, were invisible to every organisation relying on Change Healthcare for claims processing.
Critical gap: HITECH requires Business Associates to impose HIPAA-equivalent obligations on their sub-contractors. In practice, most BAAs include this language but no covered entity verifies that it has been operationalised. This fourth-party gap is precisely what the Change Healthcare attack exploited and what the 2025 NPRM is designed to close through mandatory annual vendor oversight verification.
For the full TPRM policy framework that governs BAA management, see the Neotas TPRM policy guide. For the questionnaire approach and its limitations in verifying BAA compliance, see the vendor due diligence questionnaire guide.
A compliant BAA requires eight specific provisions under HIPAA and HITECH. Missing any one creates a direct compliance gap. The sub-contractor obligation clause, required by HITECH, is present in most BAAs but verified by almost no covered entity. This fourth-party gap was central to the Change Healthcare incident and is now a target of the 2025 NPRM.
FDA requirements and medical device vendor risk management
FDA 21 CFR Part 820 (Quality System Regulation/QMSR) requires medical device manufacturers to implement documented supplier qualification processes including supplier evaluation criteria, approved supplier lists, incoming inspection, quality agreements and periodic audits. ISO 13485:2016 is the international equivalent and the standard due diligence threshold for health systems assessing device vendors. Connected medical devices additionally require MDS2 attestation and, per FDA’s 2023 cybersecurity guidance, a Software Bill of Materials (SBOM). These requirements are entirely separate from HIPAA and must be assessed independently.
Medical device vendor risk sits in a regulatory category that most healthcare TPRM programmes treat as a cybersecurity problem. It is not. FDA compliance status, active 483 observations, consent decrees and product recall history are the primary risk indicators for a medical device supplier. An annual cybersecurity questionnaire will not find any of them.
FDA 21 CFR Part 820 and QMSR: supplier qualification requirements
The FDA Quality System Regulation requires medical device manufacturers to maintain documented supplier qualification programmes. For health systems assessing a medical device vendor, the relevant due diligence items are: FDA registration status and current compliance, any active 483 observations or Warning Letters, history of consent decrees or product recalls in the relevant product lines, and evidence of an ISO 13485-certified quality management system.
A device manufacturer operating under an active FDA consent decree is not simply a regulatory compliance problem for that manufacturer. It is a procurement risk for every health system using their products. The consent decree may restrict production, require third-party auditing, and create supply continuity risk that a standard vendor questionnaire will not disclose. Active regulatory enforcement against a medical device supplier is a critical TPRM flag that requires independent intelligence investigation, not self-certification.
The FDA’s device inspection database and public 483 records are accessible at fda.gov medical device databases. These should be checked independently for every Critical medical device vendor as part of the pre-onboarding due diligence process.
MDS2 attestation and SBOM for connected medical devices
Connected medical devices, those networked into clinical systems or capable of transmitting patient data, create simultaneous cybersecurity and clinical risk. Two specific assessment requirements apply only to this category and appear in almost no general TPRM framework:
MDS2 (Manufacturer Disclosure Statement for Medical Device Security). A standardised disclosure form that medical device manufacturers complete, covering cybersecurity capabilities, data handling practices and network connectivity requirements. Requiring a current MDS2 from every connected device vendor is a healthcare-specific due diligence step. An outdated MDS2 (more than 12 months old) for an actively deployed connected device is itself a risk indicator.
Software Bill of Materials (SBOM). FDA’s December 2023 medical device cybersecurity guidance requires manufacturers to provide an SBOM: a complete inventory of every software component in the device. This enables health systems to assess whether any component contains known critical vulnerabilities (via NIST NVD cross-reference) or incorporates software sourced from entities subject to US sanctions. The SBOM requirement is now a standard pre-procurement assessment item for Tier 1 medical device vendors.
Pharmaceutical supply chain and API sourcing risk
Pharmaceutical vendor risk involves a supply chain dimension that sits entirely outside cybersecurity frameworks. Active Pharmaceutical Ingredient (API) sourcing concentration, where a generic drug’s API comes from a single manufacturing region or a small number of facilities, creates supply disruption risk and potential sanctions exposure that standard questionnaires cannot detect.
The FDA’s Drug Shortages database consistently shows that concentration in API manufacturing creates systemic supply vulnerability in the US pharmaceutical market. FDA Drug Shortages database. A pharmaceutical procurement team conducting TPRM on a key generic drug supplier should assess API sourcing geography and concentration as part of the financial stability and supply continuity risk category.
For UK pharmaceutical organisations, the Modern Slavery Act 2015 requires annual supply chain transparency statements covering due diligence on labour practices across the entire supply chain, including API manufacturers and contract research organisations operating in high-risk manufacturing regions. This intersects with the ESG obligations covered in the next section. For supply chain risk management services aligned to pharmaceutical procurement, see the Neotas supply chain risk management guide.
Medical device vendors require FDA 21 CFR and ISO 13485 assessment alongside standard cybersecurity checks. Connected devices require MDS2 attestation and SBOM review. Pharmaceutical suppliers require API sourcing assessment and, for UK organisations, Modern Slavery Act compliance verification. None of these requirements are addressed by standard HIPAA-focused questionnaire programmes.
ESG, Modern Slavery and ethical supply chain obligations in healthcare vendor management
ESG obligations in healthcare vendor management include: Modern Slavery Act 2015 supply chain due diligence for UK organisations above £36 million turnover; CSDDD and CSRD reporting obligations for EU-operating health systems; FCPA and UK Bribery Act exposure from vendor executive connections to public officials; sanctions screening for pharmaceutical and medical device component sourcing; and labour practice monitoring across clinical staffing agencies and pharmaceutical manufacturing supply chains. This is the most underserved category in healthcare TPRM and the one most likely to create regulatory and reputational exposure that questionnaire programmes cannot detect.
No competitor in the current top 10 search results for “healthcare vendor risk management” covers ESG obligations at any meaningful depth. This is not because the obligations are obscure. It is because most healthcare TPRM providers are cybersecurity companies that have added a compliance checklist. ESG due diligence requires intelligence-led investigation, not questionnaire responses.
Modern Slavery Act obligations for healthcare procurement
Section 54 of the Modern Slavery Act 2015 requires commercial organisations with annual turnover of £36 million or more, that supply goods or services in the UK, to publish an annual transparency statement covering their supply chain due diligence on labour practices. For NHS Trusts, private hospital groups, pharmaceutical manufacturers and large medical device distributors operating in the UK, this is a current legal obligation.
The practical implications for vendor management are specific. Clinical staffing agencies operating in high-risk recruitment regions, pharmaceutical contract manufacturers in jurisdictions with documented labour violations, and medical device component suppliers sourcing from conflict-affected areas all create potential Modern Slavery Act exposure. A signed supplier questionnaire asserting compliance is not sufficient evidence under the Act’s reasonable steps standard. Independent adverse media screening and supply chain investigation are required. For the full ESG due diligence framework applicable to these vendor relationships, see Neotas ESG due diligence services.
FCPA and UK Bribery Act exposure in clinical procurement
Healthcare procurement involves substantial government contract exposure, particularly for organisations supplying Medicare, Medicaid, NHS or other public healthcare systems. Vendor executive connections to public officials, procurement officers or government-linked decision-makers create direct FCPA and UK Bribery Act exposure for the purchasing organisation. A medical device distributor whose senior sales officer maintains an undisclosed relationship with a hospital procurement director is a FCPA risk for the health system, not just the distributor.
This category of risk is entirely invisible to cybersecurity questionnaires and standard sanctions database checks. It requires investigation of vendor executive networks, beneficial ownership structures and third-party intermediary relationships. The financial crime compliance layer of healthcare vendor due diligence specifically addresses this exposure.
Sanctions screening for pharmaceutical and device supply chains
Pharmaceutical API sourcing from manufacturers in sanctioned jurisdictions, medical device component procurement from entities connected to sanctioned parties, and healthcare SaaS platforms owned through corporate structures that include sanctioned individuals all create OFAC and UK sanctions exposure for health systems. Standard vendor database checks run against the vendor’s registered corporate identity. They do not investigate the vendor’s sub-contractor networks, component suppliers or beneficial ownership chains.
A pharmaceutical manufacturer operating in compliance with US export regulations may still source APIs from a facility whose parent company has indirect connections to sanctioned entities in its supply chain. Detecting this requires beneficial ownership analysis and supply chain mapping. It cannot be achieved through questionnaire self-certification.
ESG healthcare vendor risk: what to assess
Modern Slavery Act compliance across clinical staffing and pharmaceutical manufacturing supply chains. FCPA/UK Bribery Act exposure from vendor executive government connections. Sanctions proximity screening for pharmaceutical API and medical device component sourcing. CSDDD/CSRD supply chain reporting obligations for EU-active health systems. Labour practice violations in contract research organisations and clinical trial management companies. Conflict mineral exposure in medical device component supply chains.
ESG obligations in healthcare vendor management are not aspirational commitments. Modern Slavery Act duties, FCPA exposure from vendor executive connections, and sanctions screening for pharmaceutical supply chains are current legal obligations with regulatory and reputational consequences. No questionnaire-based programme can detect these risks adequately. Intelligence-led OSINT investigation is the only effective control.
The 7 healthcare vendor categories and their regulatory risk profiles
Healthcare organisations work with a wider range of vendor types than almost any other sector. Each category carries a distinct regulatory obligation, primary risk domain and due diligence requirement. Treating all vendors identically is the most common structural failure in healthcare TPRM programmes.
| Vendor type | Risk tier | Primary regulatory obligation | ESG/integrity flag | Primary failure risk |
|---|---|---|---|---|
| EHR and clinical software | Critical | HIPAA BAA, SOC 2, NIST CSF, 2025 NPRM MFA/encryption | Beneficial ownership; executive integrity | Mass PHI exposure and clinical operations disruption |
| Medical device manufacturers | Critical | FDA 21 CFR Part 820, ISO 13485, MDS2, SBOM, HIPAA BAA if connected | Component sourcing sanctions; conflict mineral exposure | Patient safety event and data breach via networked devices |
| Cloud and SaaS providers | Critical | HIPAA BAA, SOC 2 Type II, ISO 27001, 2025 NPRM encryption/MFA | Sub-contractor concentration; data residency | Data breach and operational downtime at scale |
| Revenue cycle and billing | High | HIPAA BAA, PCI DSS, concentration risk assessment | Financial distress signals; beneficial ownership | Financial fraud, PHI exposure and revenue cycle disruption |
| Diagnostic labs and imaging | High | HIPAA BAA, CLIA certification, accreditation status | Regulatory actions; accreditation lapse | Clinical error and PHI exposure |
| Telehealth platforms | High | HIPAA BAA, FTC Health Breach Notification Rule, 2025 NPRM | Adverse media; investor disclosure obligations | Real-time patient data breach and care disruption |
| Pharmaceutical and API suppliers | High | FDA GMP 21 CFR Part 211, ICH Q10, Modern Slavery Act (UK), CSDDD (EU) | Labour violations; API sourcing concentration; sanctions proximity | Drug safety event, ESG violation and supply disruption |
Each healthcare vendor category carries distinct regulatory obligations and risk profiles. Critical vendors, including EHR providers, medical device manufacturers and cloud SaaS providers, require full intelligence-led assessment across all six risk domains. Pharmaceutical and API suppliers add ESG, sanctions and FDA GMP obligations that no cybersecurity-focused questionnaire addresses.
What healthcare vendor questionnaires cannot find
Vendor questionnaires surface information the vendor is willing and able to disclose. They cannot detect adverse media in non-English press, beneficial ownership opacity in multi-layer corporate structures, financial distress signals before formal disclosure, regulatory actions in other jurisdictions, sub-contractor concentration risk, or executive-level integrity issues. In healthcare, these are precisely the risks most likely to produce serious incidents. Intelligence-led OSINT screening is the control that closes this gap.
Every healthcare TPRM guide recommends questionnaires. None acknowledge their fundamental structural limitation: a questionnaire is a self-reporting tool. It reveals what vendors choose to reveal and what vendors know about themselves. The Change Healthcare breach was prefigured by publicly available security researcher disclosures that no questionnaire cycle captured. That information existed. The programme was not designed to find it.
The six specific gaps in questionnaire-based healthcare TPRM
1. Adverse media in non-English press. A pharmaceutical manufacturer with documented GMP violations covered extensively in its home country’s press. A medical device distributor linked to bribery allegations in an emerging market. A clinical staffing agency with labour practice violations reported in regional news. Structured databases capture this weeks or months after the fact, if at all. OSINT screening across 200 or more languages surfaces it at the time of assessment.
2. Beneficial ownership opacity. A healthcare SaaS vendor owned through a chain of holding companies, one layer of which contains a party connected to a sanctioned individual. No questionnaire asks about the full beneficial ownership chain to the ultimate beneficial owner. Network analysis investigation surfaces it. This directly creates sanctions exposure for the health system procuring the service, regardless of whether the vendor disclosed the ownership structure.
3. Financial distress signals before formal disclosure. A pharmacy benefits manager in early financial difficulty. The signs are visible before public filings: adverse credit indicators, supplier payment delays, executive departures, debt covenant issues, and changes in audit engagement. Financial intelligence monitoring detects these months before they appear in structured data sources.
4. Regulatory actions in other jurisdictions. A medical device manufacturer with an active FDA 483 observation in one product line did not include it in their self-certification questionnaire response. Enforcement actions in the vendor’s home jurisdiction that do not automatically translate to US or UK regulatory records. Independent regulatory status investigation across multiple jurisdictions surfaces these. See Neotas enhanced due diligence services for the investigation methodology.
5. Sub-contractor concentration risk. Two critical EHR vendors both relying on the same cloud infrastructure provider in the same geographic region. Neither discloses this because it is considered proprietary information. Network analysis and fourth-party mapping surfaces the shared dependency and the concentration risk it creates across the vendor portfolio.
6. Executive-level integrity risks. A vendor’s senior leadership team with undisclosed connections to public officials: a direct FCPA or UK Bribery Act risk for the health system if not detected pre-onboarding. PEP screening, political connection mapping and social network analysis are the investigative tools that surface these risks. A standard questionnaire asking “do your executives have any conflicts of interest?” will not find them.
What Change Healthcare proved about questionnaire programmes
Security researchers had raised concerns about Change Healthcare’s security architecture in the months before the February 2024 ransomware attack. The information was publicly available in open-source forums and security researcher publications. An annual questionnaire cycle, run at the standard 12-month interval, would not have captured this. A continuous monitoring programme with adverse media and security researcher disclosure scanning would have.
Most affected health systems had BAAs in place. Many had current security questionnaires on file. What they lacked was independent intelligence monitoring of a vendor whose questionnaire responses attested compliance while publicly available open-source information told a different story. This is not a failure of the questionnaire content. It is a structural limitation of self-reporting as a risk management control. For the OSINT investigation methodology that closes this gap, see OSINT tools and techniques in vendor screening.
Questionnaire-based healthcare TPRM cannot detect six categories of risk: adverse media in non-English sources, beneficial ownership opacity, pre-disclosure financial distress, multi-jurisdiction regulatory actions, sub-contractor concentration risk and executive integrity issues. Change Healthcare demonstrated what happens when a critical vendor’s real risk profile diverges from its questionnaire responses. Intelligence-led OSINT screening is the control designed to catch this divergence.
The healthcare vendor risk assessment process: 7 stages
A complete healthcare vendor risk assessment follows a structured lifecycle. The process is continuous and does not end at onboarding. For the full TPRM lifecycle methodology, see the Neotas TPRM lifecycle guide.
| Stage | What happens | Healthcare-specific requirement | 2025 NPRM implication | Most common failure |
|---|---|---|---|---|
| 1. Vendor inventory | Map every vendor with PHI access, clinical system access or patient-critical supply chain role | Include all Business Associates and HITECH sub-contractors | Annual technology asset inventory becomes mandatory documentation | Most hospitals find 30-50% more vendors than their records show |
| 2. Risk tiering | Classify vendors by PHI access, clinical criticality, FDA category, concentration risk and ESG exposure | BAA requirement determines minimum due diligence threshold; clinical criticality determines tier | All ePHI-handling vendors require explicit MFA and encryption verification | Tiering by vendor category rather than actual PHI access level |
| 3. Pre-onboarding due diligence | Tier-proportionate assessment before any PHI access begins | Critical vendors: intelligence-led full assessment. Standard: questionnaire plus BAA verification | Independent security control verification required; self-certification alone insufficient | Relying entirely on self-completed questionnaires for critical vendors |
| 4. BAA and contract controls | Signed BAA before any PHI handling; contract provisions for breach notification, audit rights, sub-contractor disclosure | BAA must satisfy all 8 HIPAA/HITECH required provisions | 24-hour breach notification timeline replaces 60-day default under proposed rule | Generic BAA templates missing HITECH sub-contractor obligations |
| 5. Ongoing monitoring | Continuous monitoring for adverse media, regulatory actions, security incidents and financial distress signals | Annual questionnaire alone does not satisfy HIPAA ongoing due diligence requirement | Annual compliance audit requirement mandates continuous monitoring infrastructure | Annual-only reviews: most incidents happen between review cycles |
| 6. Issue management | Defined escalation paths and response timelines when monitoring flags a risk | OCR examines issue management records during investigations | Documented risk response records become an audit deliverable under the proposed rule | Alerts fire but no defined action path exists for the compliance team |
| 7. Offboarding | PHI return or certified destruction, access revocation, BAA termination, documented closeout | HIPAA requires documented PHI disposition at relationship end | Asset inventory must reflect vendor removal and PHI access termination | Residual PHI access left active months after the relationship ends |
The healthcare vendor risk assessment lifecycle runs 7 stages from inventory through offboarding. The most common failures are underounting vendors in inventory, relying on questionnaires alone at stage 3 for critical vendors, and substituting annual reviews for continuous monitoring at stage 5. The 2025 NPRM makes all three of these failures explicitly non-compliant once finalised.
How to build a healthcare vendor risk management programme: 8 steps
Building a healthcare TPRM programme that satisfies HIPAA, FDA, ESG and the 2025 NPRM simultaneously requires a structured approach. Most programmes fail by deploying technology before governance and tiering exist. The eight-step sequence below follows the order that matters. For a full implementation framework, see the Neotas TPRM framework guide.
Governance
Define what constitutes a vendor within your organisation: Business Associates, HITECH sub-contractors, staffing agencies, clinical equipment suppliers and pharmaceutical procurement partners. This definition must be board-approved and documented in your TPRM policy before any other work begins.
Inventory
Include all Business Associates and HITECH sub-contractors handling PHI. Expect to find 30 to 50% more vendor relationships than your current records show. The 2025 NPRM makes this inventory an annual regulatory document. Under the proposed rule, the inventory must include all technology assets with ePHI access, effectively making the vendor inventory and the technology asset inventory the same compliance artefact.
Tiering
Critical (Tier 1): PHI access plus clinical criticality plus any FDA-regulated category. Important (Tier 2): PHI access without direct clinical criticality, or ESG-flagged supplier categories. Standard (Tier 3): non-PHI vendors with no direct clinical or supply chain dependency. No vendor handling PHI should fall below Tier 2. Use the vendor risk assessment template as the tiering documentation starting point.
Due Diligence Design
Tier 1 due diligence covers all six risk domains: cybersecurity, regulatory compliance, patient safety/clinical continuity, reputational/adverse media, financial stability/concentration, and ESG/ethical supply chain. Tier 2 covers cybersecurity, regulatory and adverse media at minimum. Tier 3 covers questionnaire plus BAA verification only. See Neotas enhanced due diligence services for Tier 1 assessment methodology.
Contracts
Develop a BAA template covering all 8 mandatory provisions. Update the breach notification timeline from 60 days to 24 or 48 hours in anticipation of the NPRM finalisation. Add sub-contractor disclosure obligations: the BA must provide a list of sub-contractors handling PHI and evidence that HIPAA-equivalent safeguards have been imposed on each one. This converts the HITECH obligation from a contractual representation to a verifiable operational requirement.
Monitoring
Annual questionnaires alone do not satisfy HIPAA’s ongoing due diligence requirement. The 2025 NPRM elevates this to a mandatory annual audit obligation with documented vendor oversight verification. Critical vendors require real-time or monthly monitoring. Important vendors require quarterly review. Standard vendors require annual review. Define the monitoring infrastructure and alert routing before deploying.
Issue Management
OCR investigations examine issue management records closely. A monitoring programme that fires alerts without a documented response path is not a programme: it is an audit liability. Define escalation triggers, response timelines and sign-off requirements in writing before any monitoring goes live. HHS enforcement reviews examine whether alerts were received and whether documented action followed.
Governance Reporting
Maintain a vendor register in a format accessible for OCR audit requests. Report programme status, key risk indicators and open issues to the board at least quarterly. Document the entire programme in a formal TPRM policy that references all applicable regulatory frameworks. The programme documentation is itself an OCR audit deliverable under both current HIPAA requirements and the proposed 2025 NPRM.
Building a healthcare TPRM programme requires governance before technology, tiering before assessment design, and monitoring infrastructure before alerts go live. The 8-step sequence is designed to satisfy HIPAA, FDA, ESG and the 2025 NPRM requirements simultaneously without building compliance gaps into the foundation.
How Neotas supports healthcare vendor risk management
Neotas is an intelligence-led third-party risk management provider, rated in the Chartis FCC50 as a leading financial crime compliance technology provider. Healthcare organisations use Neotas specifically for the intelligence layer that questionnaire platforms and cybersecurity rating tools cannot provide: the six risk categories that self-reporting structurally misses.
| Neotas capability | Healthcare risk category addressed | What it delivers |
|---|---|---|
| Intelligence-led vendor due diligence | All six risk domains | OSINT-enhanced assessment covering cybersecurity, financial health, regulatory standing, adverse media, beneficial ownership and ESG indicators simultaneously |
| Adverse media screening | Reputational and adverse media risk | 200+ languages covering traditional press, social media and emerging sources. Surfaces risks weeks before structured database updates. |
| Beneficial ownership analysis | Financial crime and sanctions risk | Multi-layer corporate structure investigation to identify sanctions exposure, PEP connections and undisclosed conflicts of interest in vendor ownership chains |
| Financial distress monitoring | Financial stability and concentration risk | Early warning signals from payment behaviour, credit indicators, executive departure patterns and regulatory filings, often months before formal disclosure |
| ESG and ethical supply chain screening | ESG, Modern Slavery and FCPA risk | Pharmaceutical API sourcing assessment, labour practice violation screening, ABAC indicators and UK Modern Slavery Act compliance evidence across vendor supply chains |
| Continuous monitoring | All six categories ongoing | Automated alerts for adverse media, sanctions changes, regulatory actions and financial health signals. Closes the annual-review gap that the Change Healthcare incident and the 2025 NPRM both require addressing. |
| Financial crime compliance integration | Regulatory and financial crime risk | Sanctions screening, PEP checks and AML indicators embedded in vendor due diligence. Relevant for pharmaceutical and medical device supply chains with complex international ownership structures. |
Build a healthcare TPRM programme that goes beyond questionnaires
Neotas works with compliance leads, procurement directors and risk teams at health systems, pharmaceutical companies and health tech firms across the UK and US. We provide the intelligence layer that questionnaire-only programmes cannot reach: adverse media in 200+ languages, beneficial ownership investigation, financial distress signals and ESG screening across your full vendor population.
Healthcare vendor risk management in practice: what intelligence-led screening found
Each of the following engagements involved a vendor that returned clean results on standard database checks. Intelligence-led OSINT screening found the risk before it became the client’s problem.
Supply chain risk identified before a pharmaceutical partnership contracted
A healthcare procurement team needed due diligence on a prospective pharmaceutical partner beyond standard database checks. OSINT screening surfaced adverse media, undisclosed regulatory actions and reputational risk indicators invisible to structured data sources. The engagement prevented a high-value partnership with a materially compromised supplier operating under regulatory scrutiny in its home jurisdiction. Read the supply chain OSINT case study
ESG screening uncovers vendor supply chain exposure
A global organisation commissioned ESG risk screening on its vendor population. Labour practice violations and environmental breaches were identified in a Tier 2 supplier: the kind of sub-contractor visibility that healthcare TPRM programmes must demonstrate under Modern Slavery Act and CSDDD obligations. The findings were invisible to the vendor’s self-reported ESG questionnaire responses. Read the ESG supply chain case study
Third-party risk surfaced through OSINT that database checks missed entirely
A regulated organisation needed vendor due diligence beyond questionnaire-based assessment for a critical technology partner. Neotas OSINT screening surfaced adverse media, undisclosed corporate connections and reputational red flags that structured data sources had missed entirely. The investigation covered foreign-language press coverage and historical regulatory proceedings in two jurisdictions not covered by standard databases. Read the full TPRM OSINT case study
Beneficial ownership analysis reveals sanctions proximity in procurement counterparty
Standard corporate checks on a medical device procurement counterparty returned clean results. Neotas network analysis mapped undisclosed corporate relationships through a chain of three holding company layers, identifying a beneficial owner with sanctions proximity that created direct OFAC exposure for the procuring health system. The risk was invisible to any database-only screening approach. Read the network analysis case study
Frequently asked questions about healthcare vendor risk management
Further reading
What is TPRM? Complete 2026 guide
The definitive guide to third-party risk management methodology, lifecycle stages, frameworks and programme maturity. Essential context for healthcare TPRM teams building from a general framework baseline.
Healthcare TPRM platform overview
How Neotas delivers continuous, audit-ready TPRM for healthcare organisations, covering automated vendor compliance across HIPAA, FDA QMSR, NIS2, CQC and GDPR in a single platform.
Third-party risk management framework guide
A detailed framework implementation guide covering governance design, vendor tiering models, due diligence process architecture and monitoring infrastructure for regulated industries including healthcare.
TPRM lifecycle: stages and best practices
The full TPRM lifecycle from initial vendor inventory through offboarding, with detailed guidance on the continuous monitoring stage that the 2025 HIPAA NPRM requires formalising.
How Neotas conducts ESG and ethical supply chain due diligence, covering Modern Slavery Act compliance verification, FCPA exposure mapping and pharmaceutical supply chain labour practice assessment.
Covers fourth-party dependency mapping, pharmaceutical API sourcing concentration risk, sub-contractor chain investigation and the OSINT techniques used to surface supply chain risks beyond questionnaire data.
Enhanced due diligence services
Neotas intelligence-led vendor assessment methodology for Critical (Tier 1) vendor relationships, combining OSINT investigation with structured database checks and analyst-led investigation across all six risk domains.
Vendor-specific due diligence process and methodology, covering the standard assessment criteria for HIPAA-scope vendors and the additional checks required for medical device and pharmaceutical supply chain relationships.
How to write and structure a TPRM policy that satisfies HIPAA OCR audit requirements, covers all five regulatory frameworks applicable to healthcare, and provides the governance documentation the 2025 NPRM requires.
OSINT tools and techniques in vendor screening
The open-source intelligence investigation methodology Neotas uses to surface vendor risks that questionnaire programmes structurally cannot detect, including adverse media in 200+ languages and beneficial ownership mapping.
Categories: Third-Party Risk Management, Healthcare, Regulatory Compliance
Tags: Healthcare vendor risk management, HIPAA TPRM, BAA compliance, FDA 21 CFR Part 820, healthcare third party risk, vendor due diligence healthcare, HIPAA security rule 2025, ESG healthcare vendors, Change Healthcare breach, pharmaceutical supply chain risk, medical device vendor risk, healthcare OSINT screening
